Built by Investors, for Investors
We started Sentinel because we got burned. Now we make sure others don't.
The OTC information gap is a feature, not a bug.
The OTC market trades over $400 billion in annual volume across more than 12,000 securities — and the majority of that universe has no institutional research coverage. The vacuum gets filled by promoter-funded press releases, paid newsletter touts, and recycled investor decks.
Sentinel was founded to be the institutional-grade alternative: independent, conflict-free, methodology-driven research on the OTC market. We do not take stock as compensation. We do not maintain promotional relationships. We do not advise the companies we cover.
Our mission: to bring institutional-grade transparency to the OTC market.
The people behind every rating.
Founded Sentinel after watching the OTC information gap erode capital for years. Leads research methodology and final report sign-off.
Open seat — verification, filings, and financial integrity workstream.
Open seat — XBRL validation, restatement analysis, going-concern review.
Open seat — customer outreach, facility verification, supplier tracing.
Advisors
Four commitments. No exceptions.
Independence above all
We do not take equity from issuers we cover. Ever.
Data over narrative
Primary filings beat press releases. Every time.
Transparency in methodology
Our framework is public. No black boxes.
Accountability in every rating
Every score is reviewable, defensible, and tied to evidence.